Screening for type 2 diabetes: a short report for the National Screening Committee
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) has been increasing, owing to increases in overweight and obesity, decreasing physical activity and the changing demographic structure of the population. People can develop T2DM without symptoms and up to 20% may be undiagnosed. They may have diabetic complications, such as retinopathy, by the time they are diagnosed, or may suffer a heart attack, without warning. Undiagnosed diabetes can be detected by raised blood glucose levels. AIM: The aim of this review was to provide an update for the UK National Screening Committee (NSC) on screening for T2DM. METHODS: As this review was undertaken to update a previous Health Technology Assessment review published in 2007, and a more recent Scottish Public Health Network review, searches for evidence were restricted from 2009 to end of January 2012, with selected later studies added. The databases searched were MEDLINE, EMBASE, MEDLINE-in-Process & Other Non-Indexed Citations, Science Citation Index and Conference Proceedings Citation Index. The case for screening was considered against the criteria used by the NSC to assess proposed population screening programmes. RESULTS: Population screening for T2DM does not meet all of the NSC criteria. Criterion 12, on optimisation of existing management, has not been met. A report by the National Audit Office (NAO) gives details of shortcomings. Criterion 13 requires evidence from high-quality randomised controlled trials that screening is beneficial. This has not been met. The Ely trial of screening showed no benefit. The ADDITION trial was not a trial of screening, but showed no benefit in cardiovascular outcomes from intensive management in people with screen-detected T2DM. Criterion 18 on staffing and facilities does not appear to have been met, according to the NAO report. Criterion 19 requires that all other options, including prevention, should have been considered. A large proportion of cases of T2DM could be prevented if people avoided becoming overweight or obese. The first stage of selection would use risk factors, using data held on general practitioner computer systems, using the QDiabetes Risk Score, or by sending out questionnaires, using the Finnish Diabetes Risk Score (FINDRISC). Those at high risk would have a measure of blood glucose. There is no perfect screening test. Glycated haemoglobin (HbA1c) testing has advantages in not requiring a fasting sample, and because it is a predictor of vascular disease across a wider range than just the diabetic one. However, it lacks sensitivity and would miss some people with diabetes. Absolute values of HbA1c may be more useful as part of overall risk assessment than a dichotomous 'diabetes or not diabetes' diagnosis. The oral glucose tolerance test is more sensitive, but inconvenient, more costly, has imperfect reproducibility and is less popular, meaning that uptake would be lower. CONCLUSIONS: When considered against the NSC criteria, the case for screening is less strong than it was in the 2007 review. The main reason is the absence of cardiovascular benefit in the two trials published since the previous review. There is a case for selective screening as part of overall vascular risk assessment. Population screening for T2DM does not meet all of the NSC criteria. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Similar findings were reported from the Finnish Diabetes Prevention Study (DPS).(15) Participants were divided into six groups according to how many lifestyle goals were achieved, so that group 5 achieved all and group 0 none.”
ResultStratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 3×
“The importance of large vessel disease can be seen in the end points reported in the UKPDS.(24) The majority of adverse events were due to large vessel disease.”
BackgroundInfluential(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · cited 1×
“As in the total UKPDS group, the end points in the control group were dominated by large vessel disease, with 157 macrovascular end points and 19 microvascular ones in the control group of 411 patients.(25)”
MethodThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J. G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69701-8 · Cited by 1,799 · cited 1×
“At 7 years, the difference had diminished slightly but the intervention group retained most of the benefit, suggesting that 4 years of the lifestyle intervention had resulted in a sustained change in lifestyle habits.(16)”
BackgroundGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974 · cited 1×
“These are somewhat different from the Khaw et al. (2004)37 results.”
ResultDay, N., Oakes, S., Luben, R., Khaw, K., Bingham, S., Welch, A., & Wareham, N. (1999) · Nature · doi:10.17863/cam.89388 · Cited by 780
Herman, W. H., Ma, Y., Uwaifo, G., Haffner, S., Kahn, S. E., Horton, E. S., Lachin, J. M., Montez, M. G., Brenneman, T., Barrett-Connor, E., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2003 · Cited by 574
Cited by
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Huth, C., von Toerne, C., Schederecker, F., de las Heras Gala, T., Herder, C., Kronenberg, F., Meisinger, C., Rathmann, W., Koenig, W., Waldenberger, M., et al. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-018-0475-8 · Cited by 56
“The main advantage of HbA1c in contrast to glucose is its spontaneous availability, avoiding fasting, which is no longer required in routine clinical practice [18], and avoiding oral glucose tolerance test (OGTT) burden [19].”
BackgroundEstlin, A. F. L., Ahern, A. L., Griffin, S. J., & Strelitz, J. (2021) · Diabetic Medicine · doi:10.1111/dme.14646 · Cited by 8
Metadata
- Authors
- Waugh, N., Shyangdan, D., Taylor-Phillips, S., Suri, G., & Hall, B.
- Venue
- Health Technology Assessment
- Published
- 2013-08
- Volume
- 17
- Issue
- 35
- Pages
- 1-90
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2115808702
- Cited by
- 130
- References
- 27
- FWCI
- 14.81
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for type 2 diabetes: a short report for the National Screening Committee. https://app.cochat.ai/papers/10.3310/hta17350
- The paper
- Waugh, N., Shyangdan, D., Taylor-Phillips, S., Suri, G., & Hall, B. (2013). Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technology Assessment. https://doi.org/10.3310/hta17350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.